Physician profile
Michael Katiraie
NPI 1730617994
$3,442.08
in general payments reported to CMS, 2019-2025
30 companies · $854 in 2025
The $854 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $508 · 2021: $859 · 2022: $370 · 2023: $340 · 2024: $512 · 2025: $854.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,574 · Education: $131.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,574.48 |
| Education | $130.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $759.07 | 2020-2025 | Repatha, Otezla, Prolia |
| Abbvie INC. | $466.37 | 2020-2025 | |
| Regeneron Healthcare Solutions, INC. | $288.08 | 2022-2023 | Dupixent |
| Teva Pharmaceuticals USA, INC. | $269.06 | 2023-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Pfizer INC. | $183.57 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $158.11 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $151.00 | 2024-2025 | Rexulti |
| Exact Sciences Corporation | $113.33 | 2023-2025 | Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $103.35 | 2024-2025 | Caplyta |
| Bayer Healthcare Pharmaceuticals INC. | $95.72 | 2021-2025 | |
| Lilly USA, LLC | $89.30 | 2024-2025 | Mounjaro, Zepbound, Kisunla |
| Ironwood Pharmaceuticals, INC | $86.99 | 2021-2024 | |
| Radius Health, INC. | $75.06 | 2024 | |
| Mannkind Corporation | $71.88 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $63.21 | 2023-2024 | Xifaxan |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $59.13 | 2020 | |
| Nestle Healthcare Nutrition INC. | $57.05 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $50.04 | 2024 | |
| Astellas Pharma US INC | $45.82 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $37.77 | 2025 | Cobenfy |
| Neurocrine Biosciences, INC. | $30.77 | 2025 | |
| Cleerly, INC. | $29.91 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Boston Scientific Corporation | $26.20 | 2024 | Bodyguardian |
| Madrigal Pharmaceuticals | $23.19 | 2025 | Rezdiffra |
| Linus Health, INC. | $23.02 | 2022 | |
| Abbott Laboratories | $18.75 | 2024 | Eterna |
| Allergan, INC. | $17.74 | 2020 | |
| Eisai INC. | $17.50 | 2021 | |
| Esperion Therapeutics, INC. | $15.96 | 2024 | Nexletol |
| Aimmune Therapeutics, INC. | $15.13 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Katiraie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.